Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery
- Conditions
- Breast Cancer
- Interventions
- Radiation: partial breast irradiation
- Registration Number
- NCT02617082
- Lead Sponsor
- Fudan University
- Brief Summary
This study is designed to evaluate the feasibility and safety of partial breast irradiation for low risk DCIS after breast-conserving surgery.
- Detailed Description
Randomized clinical trials have demonstrated that the recurrence of DCIS is low and most of the recurrence occurs around the tumor bed. Besides, cosmetic outcomes are reported better in partial breast irradiation group compared to whole breast irradiation group. However, whether or not partial breast irradiation is safety in DCIS is still unknown. The purpose of this study is to evaluate the feasibility and safety of partial breast irradiation for low risk DCIS after breast-conserving surgery.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 828
- Female
- 18~65 years old
- Pathologically confirmed DCIS, low- or intermediate- grade DCIS: (lesions of ≤2.5 cm diameter, resection margins of at least 3 mm, nuclei grade: 1-2), high grade DCIS: (lesions of ≤1 cm diameter, resection margins of at least 3 mm, nuclei grade: 3)
- Treated with breast conserving surgery
- Tumor bed is labeled with Titanium clips
- No malignancy history
- ECOG score 0~1
- Written informed consent
- DCIS of both breast
- invasive breast cancer
- Multicentric disease
- Patients underwent mastectomy
- Previous radiation therapy of breast
- Medical contraindication for radiotherapy
- Pregnant or nursing
- suspicious calcification after surgery
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description partial breast irradiation partial breast irradiation -
- Primary Outcome Measures
Name Time Method ipsilateral breast tumor recurrence 5 years
- Secondary Outcome Measures
Name Time Method occurrence of contralateral breast tumor after PBI 5 years Overall survival 5 years radiation-induced toxicity of breast assessed by CTCAE v4.0 baseline, 3 months, 6 months, and every half year to 5 years Disease free survival 5 years Complications baseline,1,2,3,4,5 years
Trial Locations
- Locations (1)
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China